The median survival times were 37.3 and 47.3 months in the EZH2‐high and EZH2‐low groups, respectively, suggesting significantly poorer survival in ESCC patients with higher expression of EZH2 (Figure 2G). Here, EZH2 is linked to esophageal squamous cell carcinoma.